Elanco Animal Health Incorporated announced on September 8, 2025, that its pet health innovation, Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets), has reached $100 million in net sales. This achievement occurred in less than eight months, making it Elanco's fastest pet health product to achieve blockbuster status in history.
This rapid sales milestone is notable, especially with a single geographic approval, positioning Credelio Quattro as one of the industry's fastest-ever blockbusters. The product, launched in January, protects dogs from fleas, ticks, heartworm disease, and three types of intestinal parasites, demonstrating strong market demand for its comprehensive coverage.
The success of Credelio Quattro reinforces Elanco's innovation momentum and its commitment to delivering high-impact solutions for pet owners and veterinarians. This product's performance, alongside Experior, further solidifies Elanco's strategy of leveraging new innovations to drive sustained growth and enhance its market position.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.